About F2g
F2g is a company based in Manchester (United Kingdom) founded in 1998. F2g has raised $353.35 million across 13 funding rounds from investors including Novartis, Gov.uk and TD Securities. The company has 27 employees as of December 31, 2020. F2g offers products and services including Antifungal Drugs and Early Access Programs. F2g operates in a competitive market with competitors including Scynexis, Amplyx Pharmaceuticals, Biosergen, Elion Therapeutics and Viamet Pharmaceuticals, among others.
- Headquarter Manchester, United Kingdom
- Employees 27 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name F2g Ltd
- Date of Incorporation 10 Jun, 1998
- Jurisdiction MANCHESTER, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
-$56.81 M (USD)-43as on Dec 31, 2021
-
EBITDA
-$64.5 M (USD)-43as on Dec 31, 2021
-
Total Equity Funding
$353.35 M (USD)
in 13 rounds
-
Latest Funding Round
$100 M (USD), Series H
Sep 12, 2024
-
Investors
Novartis
& 22 more
-
Employee Count
27
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of F2g
F2g offers a comprehensive portfolio of products and services, including Antifungal Drugs and Early Access Programs.
Medications targeting rare fungal infections through innovative development.
Initiatives providing investigational therapies for patients with fungal diseases.
People of F2g
Unlock access to complete
Unlock access to complete
Funding Insights of F2g
F2g has successfully raised a total of $353.35M across 13 strategic funding rounds. The most recent funding activity was a Series H round of $100 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in F2g
F2g has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Gov.uk and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in antimicrobial resistance treatment development.
|
Locked | Locked | Locked | |
|
ICG is recognized as a global alternative asset manager.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked |
Investor details for F2g
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by F2g
Investment portfolio details for F2g
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - F2g
Detailed financials for F2g
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
F2g Comparisons
Peer comparison for F2g
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of F2g
F2g operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, Amplyx Pharmaceuticals, Biosergen, Elion Therapeutics and Viamet Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| Locked | Locked | Locked |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| Locked | Locked | Locked |
Anti-fungal therapeutics are developed against invasive fungal diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| Locked | Locked | Locked |
Therapies for chronic fungal infections are developed using metalloenzyme inhibitors.
|
Detailed competitors of F2g
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on F2g
Complete news archive for F2g
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about F2g
F2g was founded in 1998 and raised its 1st funding round 4 years after it was founded.
F2g is headquartered in Manchester, United Kingdom. It is registered at Manchester, Greater Manchester, United Kingdom.
Francesco Maria Lavino is the current CEO of F2g.
F2g is a funded company, having raised a total of $353.35M across 13 funding rounds to date.
As of Dec 31, 2020, the latest employee count at F2g is 27.
F2G was founded in 1998 in Manchester, United Kingdom, within the biotechnology sector. Antifungal drugs are discovered and developed to address systemic infections in immune-compromised patients, where mortality rates are elevated. Proprietary genomics technology and screening processes are employed to identify novel chemical series exhibiting potent activity. The F3 series of anti-mold compounds is advanced, including the lead candidate F901318 from the Orotomide class, which targets dihydroorotate dehydrogenase (DHODH).
F2g's top competitors include Scynexis, Amplyx Pharmaceuticals and Biosergen.
F2g offers Antifungal Drugs and Early Access Programs.
F2g has 23 investors. Key investors include Novartis, Gov.uk, TD Securities, European Investment Bank, and ICG.